{"protocolSection": {"identificationModule": {"nctId": "NCT00452400", "orgStudyIdInfo": {"id": "1222.5"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.", "officialTitle": "Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (3 - 4 Doses) Delivered by the Respimat\u00ae Inhaler in Patients With COPD"}, "statusModule": {"statusVerifiedDate": "2014-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03"}, "primaryCompletionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-26", "studyFirstSubmitQcDate": "2007-03-26", "studyFirstPostDateStruct": {"date": "2007-03-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-03-28", "resultsFirstSubmitQcDate": "2014-05-02", "resultsFirstPostDateStruct": {"date": "2014-06-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-17", "lastUpdatePostDateStruct": {"date": "2014-06-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Boehringer Ingelheim, Study Chair", "oldOrganization": "Boehringer Ingelheim"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat\u00ae inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount of the medication found in your blood)."}, "conditionsModule": {"conditions": ["Pulmonary Disease, Chronic Obstructive", "Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT"}, "enrollmentInfo": {"count": 409, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "BI 1744CL"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough FEV1 Response After 4 Weeks", "description": "Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.", "timeFrame": "Baseline and 4 weeks"}], "secondaryOutcomes": [{"measure": "Trough FEV1 Response After 1 Week", "description": "Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.", "timeFrame": "Baseline and 1 week"}, {"measure": "Trough FEV1 Response After 2 Weeks", "description": "Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Trough FVC Response After 1 Week", "description": "Trough FVC was defined as the mean of the two values obtained at 1 hour and 10 minutes prior to the pulmonary function test maneuver. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "timeFrame": "Baseline and 1 week"}, {"measure": "Trough FVC Response After 2 Weeks", "description": "Trough FVC was defined as the mean of the two values obtained at 1 hour and 10 minutes prior to the pulmonary function test maneuver. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Trough FVC Response After 4 Weeks", "description": "Trough FVC was defined as the mean of the two values obtained at 1 hour and 10 minutes prior to the pulmonary function test maneuver. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4"}, {"measure": "Peak FEV1 (0-3h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with baseline, treatment and centre (centre random, all other effects fixed).", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks"}, {"measure": "Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4"}, {"measure": "Peak FVC (0-3h) Response After 4 Weeks", "description": "Peak (0-3h) will be the maximum post-dose value during the first 3 hours. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours postdose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at day 1"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2"}, {"measure": "Peak FEV1 (0-3h) Response At Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.Means are adjusted using a mixed effects model with baseline,treatment and centre (centre random, all other effects fixed).", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1"}, {"measure": "Peak FEV1 (0-3h) Response After 1 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with baseline, treatment and centre (centre random, all other effects fixed).", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week"}, {"measure": "Peak FEV1 (0-3h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with baseline, treatment and centre (centre random, all other effects fixed).", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response at Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "baseline and day1"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 1 Week", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "Baseline and 1 week"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR) After 4 Weeks", "description": "Baseline PEFR was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "timeFrame": "4 weeks"}, {"measure": "Weekly Mean Evening PEFR After 4 Weeks", "description": "Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "timeFrame": "4 weeks"}, {"measure": "Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks", "description": "Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol (albuterol))", "timeFrame": "4 weeks"}, {"measure": "Area Under Curve From 0 to 3 Hours (AUC0-3)", "description": "AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=3.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Maximum Concentration (Cmax)", "description": "Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide in plasma.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Time From Dosing to the Maximum Concentration (Tmax)", "description": "tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide in plasma.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)", "description": "AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=3 at steady state.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)", "description": "AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=6 at steady state.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)", "description": "AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=24 at steady state.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Maximum Concentration at Steady State (Cmax,ss)", "description": "Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide in plasma at steady state.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)", "description": "tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide in plasma at steady state.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination", "description": "Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.", "timeFrame": "4 weeks"}, {"measure": "Laboratory Testing: Average Change From Baseline of Potassium", "description": "Laboratory testing: Average change from baseline of potassium measured on test-days. Pre-dose value on test day 1 is the baseline value.", "timeFrame": "Baseline and day 29"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions\n2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:\n\n   Patients must have relatively stable, moderate to severe airway obstruction with a post-bronchodilator FEV1 \\&#61619; 30% of predicted normal and \\< 80% of predicted normal and a post-bronchodilator FEV1 / FVC \\< 70% at Visit 1\n3. Male or female patients, 40 years of age or older\n4. Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded\n5. Patients must be able to perform technically acceptable pulmonary function tests and PEFR measurements, and must be able to maintain records (Patient Daily e-Diary) during the study period as required in the protocol\n6. Patients must be able to inhale medication in a competent manner from the Respimat\u00ae inhaler and from a metered dose inhaler (MDI).\n\nExclusion Criteria:\n\nSelection of relevant exclusion criteria:\n\n1. Patients with a history of asthma or a total blood eosinophil count 600/mm3.\n2. Patients with any of the following conditions:\n\n   * a diagnosis of thyrotoxicosis\n   * a diagnosis of paroxysmal tachycardia (\\>100 beats per minute)\n   * a marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval \\> 450 ms).\n   * a history of additional risk factors for Torsade de Pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT Syndrome)\n3. Patients with any of the following conditions:\n\n   * a history of myocardial infarction within 1 year of screening visit (Visit 1)\n   * a diagnosis of clinically relevant cardiac arrhythmia\n   * known active tuberculosis\n   * a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)\n   * a history of life-threatening pulmonary obstruction\n   * a history of cystic fibrosis\n   * clinically evident bronchiectasis\n   * a history of significant alcohol or drug abuse\n4. Patients who have undergone thoracotomy with pulmonary resection\n5. Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits\n6. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program\n7. Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)\n8. Pregnant or nursing women\n9. Women of childbearing potential not using a highly effective method of birth control\n10. Patients who have previously been randomized in this study or are currently participating in another study\n11. Patients who are unable to comply with medication restrictions.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1222.5.03 Boehringer Ingelheim Investigational Site", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "1222.5.07 Boehringer Ingelheim Investigational Site", "city": "Lakewood", "state": "California", "country": "United States", "geoPoint": {"lat": 33.85363, "lon": -118.13396}}, {"facility": "1222.5.14 Boehringer Ingelheim Investigational Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "1222.5.17 Boehringer Ingelheim Investigational Site", "city": "Wheat Ridge", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "1222.5.13 Boehringer Ingelheim Investigational Site", "city": "WheatRidge", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "1222.5.18 Boehringer Ingelheim Investigational Site", "city": "Stamford", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.05343, "lon": -73.53873}}, {"facility": "1222.5.15 Boehringer Ingelheim Investigational Site", "city": "Panama City", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.15946, "lon": -85.65983}}, {"facility": "1222.5.04 Boehringer Ingelheim Investigational Site", "city": "Coeur D'Alene", "state": "Idaho", "country": "United States", "geoPoint": {"lat": 47.67768, "lon": -116.78047}}, {"facility": "1222.5.22 Boehringer Ingelheim Investigational Site", "city": "Shreveport", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"facility": "1222.5.11 Boehringer Ingelheim Investigational Site", "city": "Reno", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 39.52963, "lon": -119.8138}}, {"facility": "1222.5.24 Boehringer Ingelheim Investigational Site", "city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "1222.5.12 Boehringer Ingelheim Investigational Site", "city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "1222.5.10 Boehringer Ingelheim Investigational Site", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "1222.5.05 Boehringer Ingelheim Investigational Site", "city": "Hershey", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "1222.5.02 Boehringer Ingelheim Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "1222.5.08 Boehringer Ingelheim Investigational Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "1222.5.19 Boehringer Ingelheim Investigational Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "1222.5.06 Boehringer Ingelheim Investigational Site", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "1222.5.21 Boehringer Ingelheim Investigational Site", "city": "Kileen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "1222.5.01 Boehringer Ingelheim Investigational Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "1222.5.23 Boehringer Ingelheim Investigational Site", "city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "1222.5.20 Boehringer Ingelheim Investigational Site", "city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "1222.5.039 St. Boniface General Hospital & Health Science Centre", "city": "Winnipeg", "state": "Manitoba", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "1222.5.032 Division of Respirology", "city": "Halifax", "state": "Nova Scotia", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "1222.5.038 Courtice Health Centre", "city": "Courtice", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.91682, "lon": -78.76626}}, {"facility": "1222.5.037 Kingston General Hospital", "city": "Kingston", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 44.22976, "lon": -76.48101}}, {"facility": "1222.5.031 Alpha Medical Research Inc.", "city": "Mississauga", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "1222.5.034 Pulmonary Care Clinic and Research Centre", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "1222.5.040 Respiratory Research Lab", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "1222.5.033 Centre de Recherche Clinique -CHUS", "city": "Sherbrooke", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "1222.5.035 Hopital Laval", "city": "Ste-Foy", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.75615, "lon": -71.29543}}, {"facility": "1222.5.036 Department of Respiratory Medicine", "city": "Saskatoon", "state": "Saskatchewan", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "1222.5.046 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.5.049 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.5.052 Boehringer Ingelheim Investigational Site", "city": "Gauting", "country": "Germany", "geoPoint": {"lat": 48.06919, "lon": 11.37703}}, {"facility": "1222.5.051 Boehringer Ingelheim Investigational Site", "city": "Gro\u00dfhansdorf", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "1222.5.047 Boehringer Ingelheim Investigational Site", "city": "R\u00fcdersdorf", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "1222.5.048 Boehringer Ingelheim Investigational Site", "city": "Wiesbaden", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "1222.5.058 Boehringer Ingelheim Investigational Site", "city": "Almelo", "country": "Netherlands", "geoPoint": {"lat": 52.35667, "lon": 6.6625}}, {"facility": "1222.5.056 Boehringer Ingelheim Investigational Site", "city": "Breda", "country": "Netherlands", "geoPoint": {"lat": 51.58656, "lon": 4.77596}}, {"facility": "1222.5.059 Boehringer Ingelheim Investigational Site", "city": "Eindhoven", "country": "Netherlands", "geoPoint": {"lat": 51.44083, "lon": 5.47778}}, {"facility": "1222.5.057 Boehringer Ingelheim Investigational Site", "city": "Heerlen", "country": "Netherlands", "geoPoint": {"lat": 50.88365, "lon": 5.98154}}]}, "referencesModule": {"references": [{"pmid": "25829298", "type": "DERIVED", "citation": "Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, Fogarty C. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting beta2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respir Med. 2015 May;109(5):596-605. doi: 10.1016/j.rmed.2015.02.012. Epub 2015 Mar 3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "409 patients were enrolled to the study, however 4 patients were assigned incorrect medication, so these patients were re-randomised, so only 405 patients actually started the study.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "FG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "FG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "FG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "FG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "79"}, {"groupId": "FG001", "numSubjects": "81"}, {"groupId": "FG002", "numSubjects": "80"}, {"groupId": "FG003", "numSubjects": "86"}, {"groupId": "FG004", "numSubjects": "79"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "74"}, {"groupId": "FG001", "numSubjects": "80"}, {"groupId": "FG002", "numSubjects": "73"}, {"groupId": "FG003", "numSubjects": "85"}, {"groupId": "FG004", "numSubjects": "76"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Other reasons not listed above", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "BG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "80"}, {"groupId": "BG003", "value": "86"}, {"groupId": "BG004", "value": "79"}, {"groupId": "BG005", "value": "405"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.66", "spread": "9.74"}, {"groupId": "BG001", "value": "63.81", "spread": "8.63"}, {"groupId": "BG002", "value": "63.25", "spread": "9.47"}, {"groupId": "BG003", "value": "63.55", "spread": "7.92"}, {"groupId": "BG004", "value": "63.19", "spread": "9.00"}, {"groupId": "BG005", "value": "63.30", "spread": "8.92"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "35"}, {"groupId": "BG004", "value": "33"}, {"groupId": "BG005", "value": "171"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "51"}, {"groupId": "BG004", "value": "46"}, {"groupId": "BG005", "value": "234"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough FEV1 Response After 4 Weeks", "description": "Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.014", "spread": "0.021"}, {"groupId": "OG001", "value": "0.046", "spread": "0.021"}, {"groupId": "OG002", "value": "0.082", "spread": "0.021"}, {"groupId": "OG003", "value": "0.109", "spread": "0.021"}, {"groupId": "OG004", "value": "0.118", "spread": "0.021"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0233", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.061", "ciPctValue": "95", "ciLowerLimit": "0.008", "ciUpperLimit": "0.113", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.097", "ciPctValue": "95", "ciLowerLimit": "0.044", "ciUpperLimit": "0.149", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.123", "ciPctValue": "95", "ciLowerLimit": "0.072", "ciUpperLimit": "0.175", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.132", "ciPctValue": "95", "ciLowerLimit": "0.080", "ciUpperLimit": "0.185", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Response After 1 Week", "description": "Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.029", "spread": "0.019"}, {"groupId": "OG001", "value": "0.059", "spread": "0.018"}, {"groupId": "OG002", "value": "0.108", "spread": "0.019"}, {"groupId": "OG003", "value": "0.099", "spread": "0.018"}, {"groupId": "OG004", "value": "0.140", "spread": "0.019"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.088", "ciPctValue": "95", "ciLowerLimit": "0.039", "ciUpperLimit": "0.137", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.137", "ciPctValue": "95", "ciLowerLimit": "0.088", "ciUpperLimit": "0.186", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.128", "ciPctValue": "95", "ciLowerLimit": "0.080", "ciUpperLimit": "0.176", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.024", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.120", "ciUpperLimit": "0.218", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.025", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Response After 2 Weeks", "description": "Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.023", "spread": "0.020"}, {"groupId": "OG001", "value": "0.062", "spread": "0.020"}, {"groupId": "OG002", "value": "0.099", "spread": "0.020"}, {"groupId": "OG003", "value": "0.102", "spread": "0.020"}, {"groupId": "OG004", "value": "0.105", "spread": "0.020"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.085", "ciPctValue": "95", "ciLowerLimit": "0.034", "ciUpperLimit": "0.136", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.121", "ciPctValue": "95", "ciLowerLimit": "0.070", "ciUpperLimit": "0.173", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.125", "ciPctValue": "95", "ciLowerLimit": "0.075", "ciUpperLimit": "0.175", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.128", "ciPctValue": "95", "ciLowerLimit": "0.077", "ciUpperLimit": "0.179", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response After 1 Week", "description": "Trough FVC was defined as the mean of the two values obtained at 1 hour and 10 minutes prior to the pulmonary function test maneuver. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.020", "spread": "0.033"}, {"groupId": "OG001", "value": "0.090", "spread": "0.033"}, {"groupId": "OG002", "value": "0.154", "spread": "0.033"}, {"groupId": "OG003", "value": "0.149", "spread": "0.032"}, {"groupId": "OG004", "value": "0.151", "spread": "0.033"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0127", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.110", "ciPctValue": "95", "ciLowerLimit": "0.024", "ciUpperLimit": "0.197", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.174", "ciPctValue": "95", "ciLowerLimit": "0.087", "ciUpperLimit": "0.261", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.170", "ciPctValue": "95", "ciLowerLimit": "0.084", "ciUpperLimit": "0.255", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.171", "ciPctValue": "95", "ciLowerLimit": "0.084", "ciUpperLimit": "0.258", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response After 2 Weeks", "description": "Trough FVC was defined as the mean of the two values obtained at 1 hour and 10 minutes prior to the pulmonary function test maneuver. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.000", "spread": "0.040"}, {"groupId": "OG001", "value": "0.090", "spread": "0.040"}, {"groupId": "OG002", "value": "0.171", "spread": "0.040"}, {"groupId": "OG003", "value": "0.149", "spread": "0.039"}, {"groupId": "OG004", "value": "0.148", "spread": "0.040"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0836", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.090", "ciPctValue": "95", "ciLowerLimit": "-0.012", "ciUpperLimit": "0.192", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.171", "ciPctValue": "95", "ciLowerLimit": "0.068", "ciUpperLimit": "0.274", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0037", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.150", "ciPctValue": "95", "ciLowerLimit": "0.049", "ciUpperLimit": "0.250", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0047", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.148", "ciPctValue": "95", "ciLowerLimit": "0.046", "ciUpperLimit": "0.251", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response After 4 Weeks", "description": "Trough FVC was defined as the mean of the two values obtained at 1 hour and 10 minutes prior to the pulmonary function test maneuver. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.026", "spread": "0.040"}, {"groupId": "OG001", "value": "0.068", "spread": "0.040"}, {"groupId": "OG002", "value": "0.136", "spread": "0.040"}, {"groupId": "OG003", "value": "0.146", "spread": "0.039"}, {"groupId": "OG004", "value": "0.153", "spread": "0.040"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0695", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.094", "ciPctValue": "95", "ciLowerLimit": "-0.008", "ciUpperLimit": "0.195", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0018", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.162", "ciPctValue": "95", "ciLowerLimit": "0.061", "ciUpperLimit": "0.264", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0008", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.172", "ciPctValue": "95", "ciLowerLimit": "0.072", "ciUpperLimit": "0.272", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.179", "ciPctValue": "95", "ciLowerLimit": "0.077", "ciUpperLimit": "0.281", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.013", "spread": "0.025"}, {"groupId": "OG001", "value": "0.154", "spread": "0.024"}, {"groupId": "OG002", "value": "0.175", "spread": "0.025"}, {"groupId": "OG003", "value": "0.226", "spread": "0.024"}, {"groupId": "OG004", "value": "0.228", "spread": "0.025"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.141", "ciPctValue": "95", "ciLowerLimit": "0.078", "ciUpperLimit": "0.204", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.162", "ciPctValue": "95", "ciLowerLimit": "0.099", "ciUpperLimit": "0.225", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.213", "ciPctValue": "95", "ciLowerLimit": "0.151", "ciUpperLimit": "0.275", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.031", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.214", "ciPctValue": "95", "ciLowerLimit": "0.151", "ciUpperLimit": "0.277", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with baseline, treatment and centre (centre random, all other effects fixed).", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.078", "spread": "0.026"}, {"groupId": "OG001", "value": "0.242", "spread": "0.026"}, {"groupId": "OG002", "value": "0.247", "spread": "0.026"}, {"groupId": "OG003", "value": "0.295", "spread": "0.025"}, {"groupId": "OG004", "value": "0.303", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.164", "ciPctValue": "95", "ciLowerLimit": "0.097", "ciUpperLimit": "0.231", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.034", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.102", "ciUpperLimit": "0.237", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.034", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.218", "ciPctValue": "95", "ciLowerLimit": "0.152", "ciUpperLimit": "0.284", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.034", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.225", "ciPctValue": "95", "ciLowerLimit": "0.157", "ciUpperLimit": "0.292", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.034", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.009", "spread": "0.044"}, {"groupId": "OG001", "value": "0.271", "spread": "0.043"}, {"groupId": "OG002", "value": "0.292", "spread": "0.044"}, {"groupId": "OG003", "value": "0.320", "spread": "0.042"}, {"groupId": "OG004", "value": "0.313", "spread": "0.044"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.262", "ciPctValue": "95", "ciLowerLimit": "0.150", "ciUpperLimit": "0.373", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.283", "ciPctValue": "95", "ciLowerLimit": "0.171", "ciUpperLimit": "0.395", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.311", "ciPctValue": "95", "ciLowerLimit": "0.201", "ciUpperLimit": "0.421", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.304", "ciPctValue": "95", "ciLowerLimit": "0.192", "ciUpperLimit": "0.416", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FVC (0-3h) Response After 4 Weeks", "description": "Peak (0-3h) will be the maximum post-dose value during the first 3 hours. Response is defined as change from the baseline value. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.152", "spread": "0.046"}, {"groupId": "OG001", "value": "0.440", "spread": "0.046"}, {"groupId": "OG002", "value": "0.432", "spread": "0.046"}, {"groupId": "OG003", "value": "0.449", "spread": "0.044"}, {"groupId": "OG004", "value": "0.438", "spread": "0.046"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.288", "ciPctValue": "95", "ciLowerLimit": "0.167", "ciUpperLimit": "0.409", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.280", "ciPctValue": "95", "ciLowerLimit": "0.159", "ciUpperLimit": "0.401", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.062", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.297", "ciPctValue": "95", "ciLowerLimit": "0.178", "ciUpperLimit": "0.416", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.286", "ciPctValue": "95", "ciLowerLimit": "0.164", "ciUpperLimit": "0.407", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.062", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours postdose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at day 1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.031", "spread": "0.017"}, {"groupId": "OG001", "value": "0.165", "spread": "0.017"}, {"groupId": "OG002", "value": "0.203", "spread": "0.017"}, {"groupId": "OG003", "value": "0.236", "spread": "0.017"}, {"groupId": "OG004", "value": "0.234", "spread": "0.017"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.133", "ciPctValue": "95", "ciLowerLimit": "0.090", "ciUpperLimit": "0.176", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.172", "ciPctValue": "95", "ciLowerLimit": "0.128", "ciUpperLimit": "0.215", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Median Difference (Final Values)", "paramValue": "0.204", "ciPctValue": "95", "ciLowerLimit": "0.162", "ciUpperLimit": "0.247", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Median Difference (Final Values)", "paramValue": "0.203", "ciPctValue": "95", "ciLowerLimit": "0.159", "ciUpperLimit": "0.246", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.022", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.000", "spread": "0.022"}, {"groupId": "OG001", "value": "0.186", "spread": "0.022"}, {"groupId": "OG002", "value": "0.215", "spread": "0.022"}, {"groupId": "OG003", "value": "0.218", "spread": "0.021"}, {"groupId": "OG004", "value": "0.247", "spread": "0.022"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.187", "ciPctValue": "95", "ciLowerLimit": "0.131", "ciUpperLimit": "0.243", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.215", "ciPctValue": "95", "ciLowerLimit": "0.159", "ciUpperLimit": "0.271", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.029", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.218", "ciPctValue": "95", "ciLowerLimit": "0.163", "ciUpperLimit": "0.273", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.247", "ciPctValue": "95", "ciLowerLimit": "0.191", "ciUpperLimit": "0.304", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.029", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.006", "spread": "0.024"}, {"groupId": "OG001", "value": "0.166", "spread": "0.024"}, {"groupId": "OG002", "value": "0.200", "spread": "0.024"}, {"groupId": "OG003", "value": "0.209", "spread": "0.023"}, {"groupId": "OG004", "value": "0.211", "spread": "0.024"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.159", "ciPctValue": "95", "ciLowerLimit": "0.100", "ciUpperLimit": "0.219", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.030", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.194", "ciPctValue": "95", "ciLowerLimit": "0.134", "ciUpperLimit": "0.253", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.030", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.203", "ciPctValue": "95", "ciLowerLimit": "0.144", "ciUpperLimit": "0.262", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.030", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.204", "ciPctValue": "95", "ciLowerLimit": "0.145", "ciUpperLimit": "0.264", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.030", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response At Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.Means are adjusted using a mixed effects model with baseline,treatment and centre (centre random, all other effects fixed).", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.104", "spread": "0.021"}, {"groupId": "OG001", "value": "0.259", "spread": "0.021"}, {"groupId": "OG002", "value": "0.288", "spread": "0.021"}, {"groupId": "OG003", "value": "0.335", "spread": "0.020"}, {"groupId": "OG004", "value": "0.335", "spread": "0.021"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.155", "ciPctValue": "95", "ciLowerLimit": "0.101", "ciUpperLimit": "0.209", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.185", "ciPctValue": "95", "ciLowerLimit": "0.131", "ciUpperLimit": "0.239", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.231", "ciPctValue": "95", "ciLowerLimit": "0.178", "ciUpperLimit": "0.284", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.231", "ciPctValue": "95", "ciLowerLimit": "0.177", "ciUpperLimit": "0.286", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.028", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response After 1 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with baseline, treatment and centre (centre random, all other effects fixed).", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.062", "spread": "0.024"}, {"groupId": "OG001", "value": "0.264", "spread": "0.023"}, {"groupId": "OG002", "value": "0.293", "spread": "0.024"}, {"groupId": "OG003", "value": "0.295", "spread": "0.023"}, {"groupId": "OG004", "value": "0.321", "spread": "0.024"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.202", "ciPctValue": "95", "ciLowerLimit": "0.140", "ciUpperLimit": "0.264", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.231", "ciPctValue": "95", "ciLowerLimit": "0.169", "ciUpperLimit": "0.294", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.233", "ciPctValue": "95", "ciLowerLimit": "0.172", "ciUpperLimit": "0.295", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.031", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.259", "ciPctValue": "95", "ciLowerLimit": "0.197", "ciUpperLimit": "0.322", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with baseline, treatment and centre (centre random, all other effects fixed).", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.079", "spread": "0.025"}, {"groupId": "OG001", "value": "0.243", "spread": "0.025"}, {"groupId": "OG002", "value": "0.267", "spread": "0.025"}, {"groupId": "OG003", "value": "0.282", "spread": "0.024"}, {"groupId": "OG004", "value": "0.280", "spread": "0.025"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.165", "ciPctValue": "95", "ciLowerLimit": "0.101", "ciUpperLimit": "0.228", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.189", "ciPctValue": "95", "ciLowerLimit": "0.125", "ciUpperLimit": "0.252", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.203", "ciPctValue": "95", "ciLowerLimit": "0.140", "ciUpperLimit": "0.266", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.201", "ciPctValue": "95", "ciLowerLimit": "0.137", "ciUpperLimit": "0.265", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.033", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response at Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "baseline and day1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.019", "spread": "0.028"}, {"groupId": "OG001", "value": "0.064", "spread": "0.028"}, {"groupId": "OG002", "value": "0.166", "spread": "0.027"}, {"groupId": "OG003", "value": "0.195", "spread": "0.028"}, {"groupId": "OG004", "value": "0.171", "spread": "0.028"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2392", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.045", "ciPctValue": "95", "ciLowerLimit": "-0.030", "ciUpperLimit": "0.121", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.147", "ciPctValue": "95", "ciLowerLimit": "0.072", "ciUpperLimit": "0.222", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.038", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.176", "ciPctValue": "95", "ciLowerLimit": "0.099", "ciUpperLimit": "0.253", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.152", "ciPctValue": "95", "ciLowerLimit": "0.076", "ciUpperLimit": "0.228", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 1 Week", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.018", "spread": "0.030"}, {"groupId": "OG001", "value": "0.067", "spread": "0.030"}, {"groupId": "OG002", "value": "0.156", "spread": "0.029"}, {"groupId": "OG003", "value": "0.132", "spread": "0.030"}, {"groupId": "OG004", "value": "0.118", "spread": "0.030"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0309", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.085", "ciPctValue": "95", "ciLowerLimit": "0.008", "ciUpperLimit": "0.162", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.174", "ciPctValue": "95", "ciLowerLimit": "0.098", "ciUpperLimit": "0.250", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.150", "ciPctValue": "95", "ciLowerLimit": "0.072", "ciUpperLimit": "0.228", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.040", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.137", "ciPctValue": "95", "ciLowerLimit": "0.059", "ciUpperLimit": "0.214", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.006", "spread": "0.031"}, {"groupId": "OG001", "value": "0.059", "spread": "0.031"}, {"groupId": "OG002", "value": "0.135", "spread": "0.030"}, {"groupId": "OG003", "value": "0.105", "spread": "0.031"}, {"groupId": "OG004", "value": "0.098", "spread": "0.031"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2150", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.053", "ciPctValue": "95", "ciLowerLimit": "-0.031", "ciUpperLimit": "0.137", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0024", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.129", "ciPctValue": "95", "ciLowerLimit": "0.046", "ciUpperLimit": "0.212", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.042", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0230", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.099", "ciPctValue": "95", "ciLowerLimit": "0.014", "ciUpperLimit": "0.184", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0333", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.092", "ciPctValue": "95", "ciLowerLimit": "0.007", "ciUpperLimit": "0.177", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.005", "spread": "0.031"}, {"groupId": "OG001", "value": "0.058", "spread": "0.031"}, {"groupId": "OG002", "value": "0.134", "spread": "0.030"}, {"groupId": "OG003", "value": "0.145", "spread": "0.032"}, {"groupId": "OG004", "value": "0.094", "spread": "0.031"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2158", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.053", "ciPctValue": "95", "ciLowerLimit": "-0.031", "ciUpperLimit": "0.137", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0024", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.129", "ciPctValue": "95", "ciLowerLimit": "0.046", "ciUpperLimit": "0.212", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.042", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0013", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.140", "ciPctValue": "95", "ciLowerLimit": "0.055", "ciUpperLimit": "0.225", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0376", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.090", "ciPctValue": "95", "ciLowerLimit": "0.005", "ciUpperLimit": "0.174", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR) After 4 Weeks", "description": "Baseline PEFR was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/minute", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "212.69", "spread": "4.431"}, {"groupId": "OG001", "value": "226.39", "spread": "4.367"}, {"groupId": "OG002", "value": "233.97", "spread": "4.425"}, {"groupId": "OG003", "value": "250.77", "spread": "4.244"}, {"groupId": "OG004", "value": "235.75", "spread": "4.471"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0211", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "13.705", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.070", "ciUpperLimit": "25.340", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.916", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "21.285", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.581", "ciUpperLimit": "32.990", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.951", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "38.077", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "26.607", "ciUpperLimit": "49.546", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.832", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "23.063", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "11.282", "ciUpperLimit": "34.845", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.990", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Mean Evening PEFR After 4 Weeks", "description": "Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/minute", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "77"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "224.65", "spread": "4.581"}, {"groupId": "OG001", "value": "235.09", "spread": "4.507"}, {"groupId": "OG002", "value": "246.98", "spread": "4.621"}, {"groupId": "OG003", "value": "262.88", "spread": "4.376"}, {"groupId": "OG004", "value": "250.06", "spread": "4.678"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0973", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "10.446", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.911", "ciUpperLimit": "22.803", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.283", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "22.333", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.824", "ciUpperLimit": "34.842", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.360", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "38.232", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "26.054", "ciUpperLimit": "50.409", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.192", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "25.408", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.814", "ciUpperLimit": "38.002", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.403", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks", "description": "Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol (albuterol))", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.914", "spread": "0.260"}, {"groupId": "OG001", "value": "2.393", "spread": "0.255"}, {"groupId": "OG002", "value": "3.052", "spread": "0.258"}, {"groupId": "OG003", "value": "1.949", "spread": "0.248"}, {"groupId": "OG004", "value": "2.500", "spread": "0.262"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1541", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.520", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.237", "ciUpperLimit": "0.196", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.364", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7065", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.138", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.583", "ciUpperLimit": "0.859", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.367", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0076", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.964", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.671", "ciUpperLimit": "-0.258", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.359", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2626", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.414", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.138", "ciUpperLimit": "0.311", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.369", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 3 Hours (AUC0-3)", "description": "AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=3.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "44"}, {"groupId": "OG004", "value": "58"}]}], "classes": [{"title": "Olodaterol (N=0;0;0;29;58)", "categories": [{"measurements": [{"groupId": "OG003", "value": "13.3", "spread": "37.9"}, {"groupId": "OG004", "value": "20.3", "spread": "56.0"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;0;44;44)", "categories": [{"measurements": [{"groupId": "OG003", "value": "11.6", "spread": "52.8"}, {"groupId": "OG004", "value": "21.1", "spread": "67.8"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Concentration (Cmax)", "description": "Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide in plasma.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram/milliliter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "54"}, {"groupId": "OG003", "value": "71"}, {"groupId": "OG004", "value": "69"}]}], "classes": [{"title": "Olodaterol (N=0;0;40;71;69)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.58", "spread": "51.4"}, {"groupId": "OG003", "value": "5.45", "spread": "63.5"}, {"groupId": "OG004", "value": "12.2", "spread": "76.0"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;54;71;66)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.94", "spread": "97.5"}, {"groupId": "OG003", "value": "5.24", "spread": "97.4"}, {"groupId": "OG004", "value": "10.6", "spread": "88.1"}]}]}]}, {"type": "SECONDARY", "title": "Time From Dosing to the Maximum Concentration (Tmax)", "description": "tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide in plasma.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "54"}, {"groupId": "OG003", "value": "71"}, {"groupId": "OG004", "value": "69"}]}], "classes": [{"title": "Olodaterol (N=0;0;40;71;69)", "categories": [{"measurements": [{"groupId": "OG002", "value": "0.167", "lowerLimit": "0.0830", "upperLimit": "1.00"}, {"groupId": "OG003", "value": "0.183", "lowerLimit": "0.0500", "upperLimit": "1.58"}, {"groupId": "OG004", "value": "0.200", "lowerLimit": "0.0330", "upperLimit": "1.27"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;54;71;66)", "categories": [{"measurements": [{"groupId": "OG002", "value": "2.95", "lowerLimit": "0.0830", "upperLimit": "3.38"}, {"groupId": "OG003", "value": "3.00", "lowerLimit": "0.0830", "upperLimit": "3.92"}, {"groupId": "OG004", "value": "3.00", "lowerLimit": "0.0830", "upperLimit": "3.60"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)", "description": "AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=3 at steady state.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "69"}, {"groupId": "OG004", "value": "70"}]}], "classes": [{"title": "Olodaterol (N=0;0;0;63;70)", "categories": [{"measurements": [{"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}, {"groupId": "OG003", "value": "15.6", "spread": "49.9"}, {"groupId": "OG004", "value": "27.7", "spread": "64.3"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;55;69;63)", "categories": [{"measurements": [{"groupId": "OG002", "value": "9.29", "spread": "43.3"}, {"groupId": "OG003", "value": "11.4", "spread": "69.0"}, {"groupId": "OG004", "value": "23.9", "spread": "68.9"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)", "description": "AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=6 at steady state.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "69"}]}], "classes": [{"title": "Olodaterol (N=0;0;0;55;69)", "categories": [{"measurements": [{"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}, {"groupId": "OG003", "value": "29.7", "spread": "43.0"}, {"groupId": "OG004", "value": "46.4", "spread": "57.3"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;32;50;48)", "categories": [{"measurements": [{"groupId": "OG002", "value": "21.4", "spread": "40.6"}, {"groupId": "OG003", "value": "25.6", "spread": "60.2"}, {"groupId": "OG004", "value": "49.4", "spread": "61.0"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)", "description": "AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide in plasma from 0 to time t=24 at steady state.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "39"}, {"groupId": "OG004", "value": "60"}]}], "classes": [{"title": "Olodaterol", "categories": [{"measurements": [{"groupId": "OG003", "value": "104", "spread": "40.9"}, {"groupId": "OG004", "value": "145", "spread": "55.1"}]}]}, {"title": "Olodaterol glucuronide", "categories": [{"measurements": [{"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}, {"groupId": "OG004", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Maximum Concentration at Steady State (Cmax,ss)", "description": "Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide in plasma at steady state.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram/milliliter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "72"}]}], "classes": [{"title": "Olodaterol (N=0;0;46;72;72)", "categories": [{"measurements": [{"groupId": "OG002", "value": "4.02", "spread": "46.7"}, {"groupId": "OG003", "value": "7.13", "spread": "63.8"}, {"groupId": "OG004", "value": "14.1", "spread": "83.4"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;60;72;66)", "categories": [{"measurements": [{"groupId": "OG002", "value": "4.90", "spread": "49.8"}, {"groupId": "OG003", "value": "5.55", "spread": "65.2"}, {"groupId": "OG004", "value": "11.1", "spread": "81.0"}]}]}]}, {"type": "SECONDARY", "title": "Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)", "description": "tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide in plasma at steady state.", "populationDescription": "All evaluable subjects. A subject was considered to be not evaluable if the subject had a protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "72"}]}], "classes": [{"title": "Olodaterol (N=0;0;46;72;72)", "categories": [{"measurements": [{"groupId": "OG002", "value": "0.192", "lowerLimit": "0.0830", "upperLimit": "1.02"}, {"groupId": "OG003", "value": "0.200", "lowerLimit": "0.0500", "upperLimit": "1.02"}, {"groupId": "OG004", "value": "0.200", "lowerLimit": "0.0830", "upperLimit": "1.00"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;60;72;66)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.00", "lowerLimit": "0.100", "upperLimit": "6.13"}, {"groupId": "OG003", "value": "3.00", "lowerLimit": "0.667", "upperLimit": "6.12"}, {"groupId": "OG004", "value": "3.00", "lowerLimit": "0.000", "upperLimit": "6.03"}]}]}]}, {"type": "SECONDARY", "title": "Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination", "description": "Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.", "populationDescription": "Treated set including all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "86"}, {"groupId": "OG004", "value": "79"}]}], "classes": [{"title": "Electrocardiogram QT prolonged", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}]}]}, {"title": "Blood creatine phosphokinase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Gamma-glutamyltransferase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Atrioventricular block first degree", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Sinus arrhythmia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Tachycardia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Palpitations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Testing: Average Change From Baseline of Potassium", "description": "Laboratory testing: Average change from baseline of potassium measured on test-days. Pre-dose value on test day 1 is the baseline value.", "populationDescription": "Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline and day 29", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}, {"groupId": "OG003", "value": "75"}, {"groupId": "OG004", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "spread": "NA", "lowerLimit": "0.93", "upperLimit": "1.01"}, {"groupId": "OG001", "value": "0.99", "spread": "NA", "lowerLimit": "0.94", "upperLimit": "1.05"}, {"groupId": "OG002", "value": "0.98", "spread": "NA", "lowerLimit": "0.94", "upperLimit": "1.04"}, {"groupId": "OG003", "value": "0.97", "spread": "NA", "lowerLimit": "0.92", "upperLimit": "1.02"}, {"groupId": "OG004", "value": "0.98", "spread": "NA", "lowerLimit": "0.93", "upperLimit": "1.02"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "4 weeks", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 79, "otherNumAffected": 13, "otherNumAtRisk": 79}, {"id": "EG001", "title": "Olo 2 mcg", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 2, "seriousNumAtRisk": 81, "otherNumAffected": 8, "otherNumAtRisk": 81}, {"id": "EG002", "title": "Olo 5 mcg", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 2, "seriousNumAtRisk": 80, "otherNumAffected": 12, "otherNumAtRisk": 80}, {"id": "EG003", "title": "Olo 10 mcg", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 2, "seriousNumAtRisk": 86, "otherNumAffected": 9, "otherNumAtRisk": 86}, {"id": "EG004", "title": "Olo 20 mcg", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 2, "seriousNumAtRisk": 79, "otherNumAffected": 7, "otherNumAtRisk": 79}], "seriousEvents": [{"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 79}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 79}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 80}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 79}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000029424", "term": "Pulmonary Disease, Chronic Obstructive"}], "ancestors": [{"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "asFound": "Pulmonary Disease, Chronic Obstructive", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000549647", "term": "Olodaterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M254406", "name": "Olodaterol", "asFound": "Kinesiotape", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}